Prof. Yi-Hsin Yang

Co-authors

Following

Followers

Research Focus & Metrics

Explore full metrics on Scilit

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications

1 May 2013 in Ophthalmology

Journal Article

Outdoor Activity during Class Recess Reduces Myopia Onset and Progression in School Children

Pei-Chang Wu

Chia-Ling Tsai

Hsiang-Lin Wu

Yi-Hsin Yang

Hsi-Kung Kuo

1 August 2018 in Ophthalmology

Journal Article

Myopia Prevention and Outdoor Light Intensity in a School-Based Cluster Randomized Trial

Pei-Chang Wu

Chueh-Tan Chen

Ken-Kuo Lin

Chi-Chin Sun

Chien-Neng Kuo

Yi-Hsin Yang

+11

1 November 2013 in The Lancet Oncology

Journal Article

Management of gastric cancer in Asia: resource-stratified guidelines

Lin Shen

Yan-Shen Shan

Huang-Ming Hu

Timothy J Price

Bhawna Sirohi

Li-Tzong Chen

28 May 2008 in Hepatology

Journal Article

Rapid virological response and treatment duration for chronic hepatitis C genotype 1 patients: A randomized trial

MING-LUNG Yu

Chia-Yen Dai

Jee-Fu Huang

Chang-Fu Chiu

Yi-Hsin Yang

Wan-Long Chuang

Recommended treatment for hepatitis C virus genotype 1 (HCV-1) patients is peginterferon plus ribavirin for 48 weeks. We assessed whether treatment duration of 24 weeks is as effective as standard treatment in HCV-1 patients with a rapid virological response (RVR; seronegative for hepatitis C virus [HCV] RNA at 4 weeks). Two hundred HCV-1 patients were randomized (1:1) to either 24 or 48 weeks of peginterferon-alpha-2a (180 μg/week) and ribavirin (1000–1200 mg/day) with a 24-week follow-up. The primary endpoint was a sustained virological response (SVR; seronegative for HCV RNA at 24-week follow-up). Overall, the 48-week arm had a significantly higher SVR rate (79%) than the 24-week arm (59%, P = 0.002). For 87 (43.5%) patients with an RVR, the 24-week arm had a lower SVR rate [88.9%; 95% confidence interval (CI): 80%–98%] than the 48-week arm (100%, P = 0.056). For 52 patients with low baseline viremia (<400,000 IU/mL) and an RVR, the 24-week arm had rates (CI) of relapse and SVR of 3.6% (−3%–11%) and 96.4% (89%–103%), respectively, which were comparable to those of the 48-week arm (0% and 100%) with difference (CI) of 3.6% (−7.2%–6.6%) and −3.6% (−14.3% to −0.6%), respectively. Multivariate analysis in all patients showed that RVR was the strongest independent factor associated with an SVR, followed by treatment duration, mean weight–based exposure of ribavirin, and baseline viral load. Conclusion: HCV-1 patients derive a significantly better SVR from 48 weeks versus 24 weeks of peginterferon/ribavirin even if they attain an RVR. Both 24 and 48 weeks of therapy can achieve high SVR rates (>96%) in HCV-1 patients with low viral loads and an RVR.